Interview 25 Apr 2018 Planting the Seeds to Grow the Italian Biotech Industry Many European countries, including the UK, France, Germany, and Switzerland, boast a thriving biotech industry. Others are still a step behind when it comes to industrializing their research. Let’s take a look at how Italy is pushing through to make it to the first league. Italy is certainly a pioneer and leader in life science research — […] April 25, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2018 Fundraising Boosts Italian Red Blood Cell Therapy EryDel has raised €26.5M to develop a red blood cell drug delivery system to treat a rare disease of the immune and nervous systems. Italian biotech EryDel has raised €26.5M to complete a Phase III trial testing a unique technology to treat ataxia telangiectasia, a rare genetic disorder. The fundraising was led by Sofinnova Partners, a leading European venture […] April 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 5 Apr 2018 French Crossover Fund Raises €275M to Invest in Medical Biotechs Sofinnova Partners has launched a crossover fund focusing on European companies to support medical biotechs across all funding stages, from seed to late stage. Sofinnova Partners, the largest French biotech VC, has launched a new fund called Sofinnova Crossover I to invest in the biopharmaceutical and medical device sectors. According to Sofinnova, the €275M fund […] April 5, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 French VC Raises the Biggest Green Biotech Fund in the World Update (15/03/2018): Sofinnova Partners has closed its fund Industrial Biotech I at €125M, making it the largest fund dedicated to driving the transition towards a more sustainable fund. 03/03/2017 Sofinnova Partners has announced the first closing of a new fund, dedicated to renewable chemistry in industrial biotech, at €106 million. The largest biotech VC in […] March 15, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2017 French Startup Raises €11M in Series A to Reinvent DNA Synthesis DNA Script has gathered the support of key international investors to take a new, faster DNA synthesis technology closer to the market. In a Series A round led by Illumina Ventures and joined by Merck Ventures and existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners, the young French startup DNA Script has raised a total […] September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 28 Jun 2017 Video: The Next Big Thing in Biotech according to Sofinnova’s Antoine Papiernik Antoine Papiernik, Managing Partner at the famous European biotech VC Sofinnova, closed Refresh this year with a keynote on the next big thing in biotech. Papiernik has more than 20 years of experience as a VC investor and has helped build major European biotechs like Actelion, ProQR or Movetis. Being part of the leading edge […] June 28, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 3 Apr 2017 Meet the Co-Founder who says DNA is the Next Silicon DNA Script opens the door to a whole new age of manufacturing synthetic DNA. Thomas Ybert, was only 30 when he co-founded the company – here’s his story! Based in Paris, DNA Script produces synthetic DNA using a proprietary template-free enzymatic technology. Most of the manufactured DNA is currently synthesized by chemical means, but this startup […] April 3, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Inside Labiotech 17 Mar 2017 Why is Sofinnova’s Rafaèle Tordjman reading Labiotech.eu? In our new series, “Leaders & Readers,” we ask different European biotech leaders to tell us why they read Labiotech.eu. This time, we talked to Rafaèle Tordjman, now Special Advisor at Sofinnova Partners, one of the most successful European biotech VCs. This interview has just been lightly edited for grammar. Why do you read Labiotech.eu? Labiotech.eu is very interesting, […] March 17, 2017 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2017 Huge Successful €103M IPO for the Next European Leader in Bioplastics Avantium has gone public and raised €103M on Euronext Amsterdam and Euronext Bruxelles with Sofinnova Partner as the main shareholder. Avantium, a spin-off from Shell, is developing renewable bioplastics made 100% from plant-based materials with the support of big partners such as Coca-Cola or Danone, for which the Dutch biotech is developing sustainable PlantBottles and yogurt cups, […] March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2017 German Biotech closes Largest Series A Fundraising of 2017 So Far Breath Therapeutics has raised €43.5M that will be used to finalize development and launch a therapy to improve survival in lung transplant patients. Sofinnova Partners, one of the top biotech VCs in Europe, and the Belgian Gimv have co-led the Series A round of Breath Therapeutics, a German company focusing on treating pulmonary orphan indications. […] March 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 How is Biotech responding to Patient Advocacy in Rare Disease? A panel of experts in rare disease discussed some of the latest trends at Labiotech Refresh, focusing on the growing patient involvement and how it is benefiting this field. Rare diseases are attracting biotech and pharma more and more since they are typically less crowded areas with unmet clinical needs. However, the lower numbers of […] December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2016 Meet one of the Most Impressive French Biotech Entrepreneurs The previous executive profiles we did, namely on Joern Aldag and Philippe Dro, are hard acts to follow, but Bernard Gilly was more than up to it. Bernard has a broad set of achievements for a broad set of lessons and takeaways. Here are the major ones. You might have seen Bernard Gilly’s name in the […] November 14, 2016 - 6 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email